alexa Regulation of VEGF-A Expression in Endothelial Cells by Transcriptional Gene Activation or Transcriptional Gene Silencing: Analysis of Genome Wide Transcriptional Response | Open Access Journals
ISSN: 2329-6682
Gene Technology
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Regulation of VEGF-A Expression in Endothelial Cells by Transcriptional Gene Activation or Transcriptional Gene Silencing: Analysis of Genome Wide Transcriptional Response

Tiia Husso1, Mikko P. Turunen1 and Seppo Yla-Herttuala1,2*
1Department of Biotechnology and Molecular Medicine, A.I.Virtanen Institute, University of Eastern Finland, Finland
2Science Service Center and Gene Therapy Unit, Kuopio University Hospital, Kuopio, Finland
Corresponding Author : Seppo Yla-Herttuala
A.I.Virtanen Institute for Molecular Sciences
University of Eastern Finland
P.O. Box 1627, FIN-70211
Kuopio, Finland
Tel: 0020 2 2683147
Received May 13, 2015; Accepted June 01, 2015; Published June 03, 2015
Citation: Husso T, Turunen MP, Yla-Herttuala S (2015) Regulation of VEGF-A Expression in Endothelial Cells by Transcriptional Gene Activation or Transcriptional Gene Silencing: Analysis of Genome Wide Transcriptional Response. Gene Technol 4:122. doi: 10.4172/2329-6682.1000122
Copyright: © 2015 Husso T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at Pubmed, Scholar Google

Visit for more related articles at Gene Technology


Vascular endothelial growth factor (VEGF-A) is an important gene in many diseases, such as cancer and cardiovascular diseases. We investigated changes in genome-wide gene expression patterns in murine endothelial cells when the expression of VEGF-A was epigenetically modulated using promoter targeted small hairpin RNAs (shRNAs). Murine endothelial cells were transduced with lentiviral vectors expressing shRNAs that are complementary to the gene promoter. Gene expression array experiments were conducted to investigate genome-wide mRNA expression changes caused by up- and downregulating VEGF-A. There were several hundreds of differentially expressed genes according to the applied statistical criteria. We noticed that the effects of downregulating VEGF-A were much more wide-spread than the effects of VEGF-A upregulation. Our in silico analysis revealed that a number of different biological processes are altered due to epigenetic effects on VEGF-A expression. One of the main regulators of VEGF-A mediated transcriptional response was found to be transcription factor ATF-4. This is the first study showing the transcriptional response to epigenetic modification of VEGF-A expression in endothelial cells. Epigenetic gene regulation represents a natural gene regulatory mechanism and these results reveal previously unknown implications of VEGF-A regulation in endothelial cells.

Transcriptional gene silencing; Transcriptional gene activation; Endothelial cell; Microarray
Vascular endothelial growth factor (VEGF-A) is a key regulator of angiogenesis in many diseases, such as cancer and cardiovascular diseases [1]. For that reason it is not surprising that its effects on endothelial cells have been studied by several approaches, such as microarray analysis [2] and next generation sequencing [3]. For example, Shin et al. used microarray analysis to study transcriptional response to human dermal lymphatic endothelial cells treated with recombinant human VEGF-A165 [4]. For the inhibition of VEGF/ VEGFR signaling, Bevacizumab has been used in a mouse xenograft model of endometrial cancer [5]. However, manipulation of VEGF-A expression, either upregulating the expression by delivering VEGF-A expression cassettes and recombinant proteins or inhibiting it by using RNAi or antibodies, is somewhat artificial in terms of endothelial biology. Recently it has become evident that small RNAs, such as miRNA, siRNA or shRNA, can regulate target gene expression via promoter targeted epigenetic modifications [6-8]. These processes have been studied in plants for a long time, but when Morris et al. [6] found that small RNAs directed to the gene promoters induce transcriptional gene silencing (TGS) and a little later Li et al. [7] showed that they can also induce transcriptional gene activation (TGA), their potential as therapeutics was quickly realized. However, the specificity and safety of these promoter targeted small RNAs must be evaluated before clinical trials.
Modulating the expression levels of mouse VEGF-A was achieved by transducing mouse endothelial cells with lentiviral vectors that express different shRNAs. These molecules are complementary to the promoter of mouse VEGF-A gene, and they are known to either increase or decrease VEGF-A expression by causing epigenetic changes in the promoter region as described previously [8,9]. Epigenetic gene regulation is a natural mechanism for altering gene expression during development and adaptation to new situations. In this study, we analyzed gene expression responses in endothelial cells after epigenetic manipulation of VEGF-A and bioinformatically predicted possible offtarget effects of these shRNAs. This data is important for the future development of this technique for clinical gene therapy.
An expanded Materials and Methods section is available in the Data Supplement.
Vector constructs
The construction of lentiviral (LV) shRNA expression vectors has been described [8]. The used target sequences were: CGTTCTCAGTGCCACAAAT (-856) and GACGCGTGTTTCAATGTGA (-451). The number in parenthesis refers to the first nucleotide in the sequence of the shRNA relative to the TSS of mouse VEGF-A promoter (U41383). As a control we used LV encoding only green fluorescent protein (GFP) without a shRNA cassette. The third generation HIV-1 based LV-PGK-GFP-U6shRNA vectors were prepared by standard calcium phosphate transfection method in 293T cells as described [10].
Transductions, sample preparation and Affymetrix analysis
C166 cells were transduced with lentiviral vector expressing either upregulating shRNA, downregulating shRNA, or LV control (referred in this report as “VEGF-A UP”, “VEGF-A DOWN” and control, respectively). Cells were transduced at 20% confluency using MOI 10 and samples were collected 7 days after the transduction. Sample preparation, hybridization and scanning were all done using standard Affymetrix protocols. The gene expression patterns of each group of cells were measured with 4 expression arrays (Affymetrix GeneChip Mouse Genome 430 2.0 Array), totaling 12 arrays.
Statistical Analysis
After preprocessing there were expression data for 17370 genes. From this set, we identified and filtered out those expression profiles where all absolute expression levels were in the lowest 10 percent of the data set. Statistical scores for these genes would be too inaccurate. 1518 genes were excluded based on this criterion. The data were then divided into three sets of four arrays each: downregulation, upregulation and control experiments. For each gene, we computed two fold changes and two differential expression p-values corresponding to “VEGF-A DOWN” experiment vs. control and “VEGF-A UP” experiment vs. control. P-values were computed with two-tailed t-test with permutation testing (10,000 permutations). To correct for multiple hypothesis testing related errors, we computed false discovery rates (FDR) using the Storey-Tibshirani procedure [11]. False discovery rate is defined as the expected ratio of the number of false positives to the total number of positive calls in a differential expression analysis between two groups of samples. The q-values, which measure the minimum FDR that occurs when calling the test significant, were also computed.
A gene is here considered to be differentially expressed if it shows both statistical and biological significance. Using p-values as a measure of statistical significance (p<0.01) and fold change (FC) (log2(FC)>0.5 for the “VEGF-A DOWN” experiment, and log2(FC)>0.25 for the “VEGF-A UP” experiment) as a measure of biological significance, the differentially expressed genes were computed for both experiments. A more stringent fold change criterion was applied in the “VEGF-A DOWN” experiment because these expression profiles deviated considerably more from the control profiles.
Gene ontology and pathway analysis
Gene ontologies, pathways affected and regulatory transcription factors were analyzed using Ingenuity Pathway Analysis tool, (IPA, by analyzing only the datasets of genes that we found significantly regulated by our own analysis.
cDNA synthesis was performed using Transcriptor First Strand cDNA Synthesis Kit (Roche) according to the manufacturer’s instructions. Real-time quantitative PCR was performed with a LightCycler 480 apparatus (Roche) using TaqMan Gene Expression Assays (Applied Biosystems) for ACTB (4352663), Tnnt2 (Mm01290256_m1), Kdr (Mm004401111_m1), Vegfa (Mm00437306_m1), Ccl2 (Mm00441242_ m1), Selp (Mm00441295_m1), Mmp13 (Mm00439491_m1), Angptl4 (Mm00480431_m1) and LightCycler 480 Probes Master (Roche). PCR cycling conditions were: 10 min at 95°C, followed by 50 cycles of 15 s at 95°C and 60 s at 60°C. Fold changes were calculated using the formula 2-(ΔΔCt), where ΔΔCt=ΔCt(shRNA) – ΔCt(GFP), and ΔCt=Ct(Target gene) – Ct(ACTB). Ct is the cycle at which the threshold line is crossed.
Based on the selected criteria, there were 326 overexpressed genes and 469 downregulated genes in the “VEGF-A UP” experiment; and 618 overexpressed genes and 587 downregulated genes in the “VEGF-A DOWN” experiment. In Figure 1, volcano plots for both experiments are shown. The spread of data points in the volcano plot is notably wider in the “VEGF-A DOWN” experiment, indicating a more widespread effect of VEGF-A modulation.
In Figure 2, VEGF-A intensities are plotted for each of the three experiments. There is a marked downregulation of VEGF-A in the downregulation experiment and a more modest upregulation of VEGF-A in the upregulation experiment. In Figure 3, we performed hierarchical clustering (with Euclidean distance and Ward’s linkage) to show that the arrays cluster correctly together according to the experiments.
It can be noted that arrays from the upregulation experiment cluster more closely with the control experiments, which means that the genome-wide effects of the downregulating shRNA are stronger. The relative expression levels of the differentially expressed genes were hierarchically clustered to investigate the proportions of up- and downregulated genes in the two experiments (Figure 4).
Clearly, the downregulation experiment yielded in much stronger expression patterns than the overexpression experiment. There are only a few genes that are differentially expressed to the same direction in both experiments. In Tables 1 and 2, the most differentially expressed genes are listed with appropriate statistical scores. Full lists of differentially expressed genes can be found in the supplementary Table 1 and 2.
Down regulation of VEGF-A
Genes that are linked to cancer (154 genes), cardiovascular disease (83 genes), developmental disorders (45 genes), inflammatory response (121 genes) and genetic disorders (67 genes) are significantly regulated in response to the downregulation of VEGF-A in endothelial cells. Top 5 molecular and cellular functions associated are: cell growth and proliferation, development, cell death, cell movement and antigen presentation.
STAT1 and CBFB transcription factors are activated in response to VEGF-A downregulation and SRF, SMAD3, HTT, HIF1A, ATF4 and TRIM24 transcription factors are inhibited by VEGF-A downregulation (Figure 5).
STAT1 and CBFB transcription factors are activated in response to VEGF-A downregulation and SRF, SMAD3, HTT, HIF1A, ATF4 and TRIM24 transcription factors are inhibited by VEGF-A downregulation (Figure 5).
Up regulation of VEGF-A
Genes that are linked to cancer (120 genes), cardiovascular disease (47 genes), inflammatory response (101 genes), immunological disease (43 genes) and connective tissue disorders (31 genes) are significantly regulated in response to the upregulation of VEGF-A in endothelial cells. Top 5 molecular and cellular functions associated are: cell growth and proliferation, cell movement, cell death, and cell-to-cell signaling and interaction.
Transcription factors ATF4, TP73, NOTCH1 and TRIM24 are activated upon the epigenetic upregulation of VEGF-A and the expression of HNF1A and TOB1 is inhibited. As in the case of downregulation of VEGF-A, these transcription factors regulate a number of genes that are further regulating other genes and signaling pathways (Figure 6).
qRT-PCR validation of differentially expressed key genes
We validated the expression of top upregulated and downregulated genes (Tnnt2, Kdr, Ccl2, Selp, Mmp13 and Angptl4) from both groups by using qRT-PCR analysis .The expression changes were very similar for all genes as in microarray analysis. Also the differential expression of VEGF-A was confirmed using qRT-PCR analysis (Figure 7).
Possible off-target effects of shRNAs
Non-specific binding of shRNA sequences to mouse gene promoters was evaluated genome-wide by aligning the shRNA binding sequences to the mouse genome (NCBI37/mm9). We then compared the gene expression levels of the genes closest to these putative binding sites to find out if they might be regulated by the shRNAs. Importantly, the predicted off-target genes showed a very little change in their expression (Table 3).
Therefore, the genes regulated in this study are likely affected by either up- or downregulation of VEGF-A and not by off-targets of shRNAs.
Vascular endothelial growth factor A (VEGF-A) is a mitogen that acts on endothelial cells and has various effects, including mediation of angiogenesis and vasculogenesis. VEGF-A is also known to have effects on vascular permeability, endothelial cell proliferation, migration, and inhibition of apoptosis [1214]. Hypoxia has been shown to induce VEGF-A expression [15]. VEGF-A has two receptors, VEGFR-1 (FLT- 1) and VEGFR-2 (FLK-1/KDR) that mediate its effects. VEGFR-2 seems to be the major mediator of angiogenesis and vascularization [16], whereas VEGFR-1 has been suggested to negatively regulate angiogenesis during embryogenesis, and positively in adulthood [17]. VEGF-A induces autophosphorylation of VEGFR-2, after which PLCγ binds to VEGFR-2, activating the MAPK/ERK cascade and proliferation of endothelial cells [18]. VEGF-A also activates other signaling pathways, such as Akt/PI3K [18]. VEGF-A has been associated with various diseases including cancer, cardiovascular diseases, and retinopathy [1921]. It has been suggested as a therapeutic agent in the treatment of myocardial ischemia by overexpressing it in the heart via viral vectors [1]. Also, VEGF-A inhibition has been studied as a potential target in cancer [22].
In this study, it was found that both the activation and inhibition of VEGF-A in endothelial cells resulted in distinctive transcriptional profiles and widespread effect in the gene expression patterns of hundreds of genes. Many of the regulated genes are in turn regulated by transcription factors. One of these transcription factors, Activating transcription factor 4 (ATF4, tax-responsive enhancer element B67, CREB2) was found to be involved in the transcriptional response of both epigenetic activation and inhibition of VEGF-A. The role of CREB2 in the regulation of VEGF-A is very interesting and warrants further studies. We have previously found H3K27 to be the most important histone residue for the epigenetic regulation of mouse VEGF-A expression [8,9]. Also, we have shown that CBP/CREB interaction inhibitor abolishes the shRNA-mediated upregulation of VEGF-A. The targeting strand of this shRNA contains one mismatch (G to T) in the middle part of the sequence and this area in the murine VEGF-A promoter contains a conserved cAMP response element (CRE). CREB, which binds to CRE [23], regulates the H3K27 acetylation by binding CREB binding protein (CBP)/p300 and CREB Regulated Transcription Coactivator (CRTC) [24]. When cells were treated with CBP-CREB interaction inhibitor, the shRNA-mediated VEGF-A upregulation was reduced to the level of shRNA control [9].
It has become obvious that in addition to targeting mRNAs in the cytoplasm as in the canonical RNAi, small non-coding RNAs can target also the genome in the nucleus, and therefore all promoter areas should be checked for possible off-target effects. In this study we observed only minor gene expression changes in genes that were close to possible offtarget sites in genome. Therefore, the gene expression changes observed with both TGS and TGA were most likely due to the regulation of VEGF-A and the action of transcription factors that are regulated. Taken together, this study analyzed the transcriptional profile of mouse endothelial cells in response to epigenetic up- or downregulation of VEGF-A and provides new leads for further analysis of VEGF-A signaling and its biological actions.
Data Accessibility
GEO files for review can be found at: geo/query/acc.cgi?token=jdwdraqcsygcgty&acc=GSE47444
We thank Genevia company, Finland, for assisting in bioinformatic analysis and A. Martikainen, J. Malinen and H. Eskelinen for technical assistance. This study was supported by grants from Finnish Academy, Sigrid Juselius Foundation and ERC Advanced grant.

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

  • 3rd World Congress on Human Genetics
    August 14-15, 2017 Edinburgh, Scotland
  • 2nd International Conference and Expo on Generic Drug Market and Contract Manufacturing
    September 25-26, 2017 Frankfurt, Germany
  • 6th International Conference and Exhibition on Cell and Gene Therapy
    Mar 27-28, 2017 Madrid, Spain
  • 2nd World Congress on Human Genetics & Genetic Disorders
    November 02-03, 2017 Toronto, Canada

Article Usage

  • Total views: 11634
  • [From(publication date):
    July-2015 - Jul 23, 2017]
  • Breakdown by view type
  • HTML page views : 7866
  • PDF downloads :3768

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

1-702-714-7001Extn: 9037

Business & Management Journals


1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

1-702-714-7001 Extn: 9042

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version